Recently, our group showed that wild type RAS proteins (including Kirsten rat sarcoma (KRAS) and HRas proto-oncogene (HRAS)) are promising novel microRNA-regulated therapeutic targets and contribute to acquired resistance to RAF inhibitors in HCC [9,10] and melanoma [11,12]. The gene discussed is KRAS; the disease is hepatocellular carcinoma.